RxDoctor Payments Data

Mark Griffin, MD

Otolaryngology/Facial Plastic Surgery · Grand Junction, CONPI 1508852971

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,020, 3.7 times the $277 reported in 2019.

$2,622in general payments, 2019–2025

Across 99 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$382
  • Kls-martin L.p.$338
  • Advanced Bionics, LLC$325
  • Medtronic$220
  • Regeneron Healthcare Solutions, Inc.$168
  • GSK$160
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,59699%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few otolaryngology/facial plastic surgery providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$185,264
Medicare patients
478
Services billed
2,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab20$75,011
Epinephrine28$5,844
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth17$1,940
Azelastine Hcl64$1,520
Ipratropium Bromide73$1,518
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort18$1,041
SynthroidLevothyroxine Sodium14$705
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav64$680
Fluticasone Propionate52$599
Calcitriol11$564
Levothyroxine Sodium57$424
Ofloxacin20$337
Ciprofloxacin Hcl27$315
Mupirocin36$307
Doxycycline Hyclate16$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$107$70514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngology/facial plastic surgery providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other otolaryngology/facial plastic surgery in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →